A Chinese medicine composition for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis

A Chinese herbal composition with a specialized preparation process addresses the limitations of Western treatments for arteriosclerosis-related conditions, offering enhanced therapeutic benefits with fewer side effects.

CN118806855BActive Publication Date: 2024-12-06HUAYI HUAYAO (SHANDONG) BIOPHARMACEUTICAL TECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411314050.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-09-20
Publication Date
2024-12-06
Estimated Expiration
2044-09-20

AI Technical Summary

Technical Problem

Current Western medical treatments for coronary heart disease, hypertension, hyperlipidemia, hyperglycemia, and hyperuricemia gout caused by arteriosclerosis are costly and have significant side effects, such as liver and kidney damage, and do not provide comprehensive recovery.

Method used

A traditional Chinese medicine composition prepared using a specific process involving 13 herbal ingredients, including Salvia miltiorrhiza, wolfberry, and a combination of enzymes, to enhance therapeutic efficacy.

Benefits of technology

The composition effectively treats and prevents the mentioned conditions with reduced side effects and improved efficacy compared to Western treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a Chinese medicine composition for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis. The preparation method comprises first extracting salvia miltiorrhiza, hawthorn and jujube seeds with a solvent, filtering to obtain an extract and a medicine residue 1; then extracting wolfberry, astragalus, polygonatum, chrysanthemum and lycium bark with alcohol to obtain an alcohol extract and medicine residue 2. Then, the medicine residue 1, the medicine residue 2, processed Polygonum multiflorum, epimedium, Ligustrum lucidum, angelica and Cuscuta australis are mixed, enzymolyzed to obtain an enzymolysis solution; finally, the extract, the alcohol extract and the enzymolysis solution are mixed, and dried to obtain. The present invention adopts a special preparation process, so that its drug efficacy is significantly enhanced, and there is a significant statistical difference compared with the positive group.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicine, and specifically relates to a traditional Chinese medicine composition for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis. Background Art

[0002] Atherosclerosis refers to a group of arteriosclerotic diseases characterized by thickening, hardening and decreased elasticity of the arterial wall, including the following three types: ① Atherosclerosis is the most common and most harmful disease; ② Calcification of the arterial media, manifested as calcium salt deposition in the media, and ossification may occur; ③ Arteriolar sclerosis is often associated with hypertension and diabetes, and its basic lesion is mainly hyalinization of small arteries.

[0003] At present, most domestic and foreign Western medicine researchers use percutaneous interventional treatment, long-term antithrombotic and anticoagulant treatment, or high-dose lipid-lowering drug treatment to stabilize ruptured or corroded plaques. However, the drugs used in the above methods can cause side effects such as liver and kidney damage when taken for a long time, which is not conducive to the patient's recovery; at the same time, the treatment cost is high, which is a heavy burden on patients.

[0004] Kangxin oral liquid / capsule, the raw materials include Chinese medicinal materials wolfberry, processed Polygonum multiflorum, epimedium, Ligustrum lucidum, angelica, Cuscuta australis, Astragalus, processed Polygonatum sibiricum, Salvia miltiorrhiza, hawthorn, Ziziphus jujuba seeds, chrysanthemum and Lycium bark; it is developed based on the formula of "Shenxian Xunlao Pills and Shenxian Bulao Pills" recorded in the Yongle Encyclopedia. It has a good effect of regulating blood lipid metabolism and anti-aging. This project further studies the preparation process in order to improve its therapeutic effect in preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis. Summary of the invention

[0005] In view of the deficiencies in the prior art, the present invention provides a Chinese medicine composition for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis.

[0006] In order to achieve the purpose of the present invention, the technical solution adopted is as follows:

[0007] A Chinese medicine composition for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis, wherein the preparation method of the Chinese medicine composition comprises the following steps:

[0008] (1) extracting salvia miltiorrhiza, hawthorn and spiny jujube seeds with a solvent, and filtering to obtain an extract and a medicinal residue 1;

[0009] (2) extracting wolfberry, astragalus, polygonatum, chrysanthemum and lycium bark with alcohol to obtain an alcohol extract and a medicinal residue 2;

[0010] (3) Mixing the residue 1, the residue 2, processed Polygonum multiflorum, Epimedium, Ligustrum lucidum, Chinese Angelica sinensis, and Cuscuta australis, and performing enzymolysis to obtain an enzymolysis solution;

[0011] (4) Mix the extract, alcohol extract and enzymatic hydrolyzate and dry them.

[0012] Furthermore, the solvent in step (1) is an aqueous solution containing 0.01-0.02% tartaric acid.

[0013] Furthermore, the extraction in step (1) is performed 1-3 times, the time for each extraction is 0.5-2 hours, and the extraction is a heating reflux extraction.

[0014] Furthermore, in step (1), the salvia miltiorrhiza is white salvia miltiorrhiza. Modern research shows that tanshinone, tanshinone and tanshinaldehyde in salvia miltiorrhiza have a certain improvement effect on atherosclerosis.

[0015] Furthermore, the alcohol extraction in step (2) is performed using 70-75% ethanol, and the extraction is a heating reflux extraction.

[0016] Furthermore, the enzyme used in the enzymolysis is a mixture of aminopeptidase, cellulase and β-glycosidase.

[0017] Furthermore, the mass ratio of aminopeptidase, cellulase and β-glycosidase is 1:0.02-0.05:0.1-0.2.

[0018] Furthermore, the temperature of the enzymolysis is 30-45° C., the time of the enzymolysis is 1-2 h, and the pH of the enzymolysis is 6-7.

[0019] The above-mentioned traditional Chinese medicine composition is prepared using 13 traditional Chinese medicinal materials in Kangxin oral liquid / capsule, including wolfberry, processed Polygonum multiflorum, epimedium, glossy privet fruit, angelica, dodder seed, astragalus, processed polygonatum, salvia miltiorrhiza, hawthorn, jujube seed, chrysanthemum and Lycium bark.

[0020] Another object of the present invention is to provide a pharmaceutical preparation comprising a Chinese medicine composition and pharmaceutically acceptable excipients.

[0021] Another object of the present invention is to provide a use of the Chinese medicine composition in the preparation of a medicament for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis.

[0022] Compared with the prior art, the present invention has the following beneficial effects:

[0023] (1) The present invention adopts 13 kinds of Chinese medicinal materials in Kangxin oral liquid / capsule, namely, wolfberry fruit, processed polygonum multiflorum, epimedium, glossy privet fruit, angelica, dodder seed, astragalus, processed polygonatum, salvia miltiorrhiza, hawthorn, spiny jujube seed, chrysanthemum and lycium bark, and is prepared to have significant therapeutic effect on preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis.

[0024] (2) The present invention adopts a special preparation process, which significantly enhances its efficacy and has significant statistical differences compared with the positive group. DETAILED DESCRIPTION

[0025] The present invention is further described below in conjunction with specific embodiments. The following parts are all parts by weight. The following enzyme reagent supplier is Nanning Dongheng Huadao Biotechnology Co., Ltd., in which the β-glycosidase is β-galactosidase.

[0026] Example 1

[0027] A Chinese medicine composition for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis, comprising the following raw materials: 18g of wolfberry, 18g of processed polygonum multiflorum, 18g of epimedium, 18g of glossy privet fruit, 24g of angelica, 36g of dodder seed, 27g of astragalus, 36g of processed polygonatum, 18g of salvia miltiorrhiza, 27g of hawthorn, 18g of spiny jujube seed, 36g of chrysanthemum and 18g of lycium bark;

[0028] The preparation method is as follows:

[0029] (1) Add 5 times the amount of aqueous solution containing 0.02% tartaric acid to white salvia miltiorrhiza, hawthorn and spiny jujube seeds, heat and reflux to extract twice, each extraction time is 0.5 h, and filter to obtain the extract and the residue 1;

[0030] (2) Mix wolfberry, astragalus, polygonatum, chrysanthemum and radix rehmanniae, add 5 times the amount of 75% ethanol, heat and reflux to extract for 1 hour, and filter to obtain the alcohol extract and residue 2.

[0031] (3) Mix the residue 1, residue 2, processed Polygonum multiflorum, Epimedium, Ligustrum lucidum, Chinese Angelica sinensis, and Cuscuta australis, add 5 times the amount of water, and then add 1% of the mass of water of a complex enzyme (a mixture of aminopeptidase, cellulase, and β-glycosidase in a mass ratio of 1:0.03:0.1), perform enzymolysis at 35°C and pH 6 for 1 hour, boil at 100°C for 3 minutes to inactivate the enzyme, and filter to obtain an enzymolysis solution;

[0032] (4) The extract, alcohol extract and enzymatic hydrolyzate are mixed, reduced pressure is applied at 60°C, and vacuum dried to obtain the product.

[0033] Example 2

[0034] A Chinese medicine composition for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis, comprising the following raw materials: 18g of wolfberry, 18g of processed polygonum multiflorum, 18g of epimedium, 18g of glossy privet fruit, 24g of angelica, 36g of dodder seed, 27g of astragalus, 36g of processed polygonatum, 18g of salvia miltiorrhiza, 27g of hawthorn, 18g of spiny jujube seed, 36g of chrysanthemum and 18g of lycium bark;

[0035] The preparation method is as follows:

[0036] (1) Add 5 times the amount of aqueous solution containing 0.01% tartaric acid to Salvia miltiorrhiza, Crataegus pinnatifida and Ziziphus jujuba seeds, heat and reflux for extraction 3 times, each extraction time is 0.5 h, and filter to obtain the extract and the residue 1;

[0037] (2) Mix wolfberry, astragalus, polygonatum, chrysanthemum and radix rehmanniae, add 5 times the amount of 70% ethanol, heat and reflux to extract for 1 hour, and filter to obtain the alcohol extract and residue 2.

[0038] (3) Mix the residue 1, residue 2, processed Polygonum multiflorum, Epimedium, Ligustrum lucidum, Chinese Angelica sinensis, and Cuscuta australis, add 5 times the amount of water, and then add 1% of the water mass of complex enzyme (the complex enzyme is a mixture of aminopeptidase, cellulase, and β-glycosidase in a ratio of 1:0.02:0.2), perform enzymolysis at 30°C and pH 7 for 2 h, boil at 100°C for 3 min to inactivate the enzyme, filter, and obtain an enzymolysis solution;

[0039] (4) The extract, alcohol extract and enzymatic hydrolyzate are mixed, reduced pressure is applied at 60°C, and vacuum dried to obtain the product.

[0040] Example 3

[0041] A Chinese medicine composition for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis, comprising the following raw materials: 18g of wolfberry, 18g of processed polygonum multiflorum, 18g of epimedium, 18g of glossy privet fruit, 24g of angelica, 36g of dodder seed, 27g of astragalus, 36g of processed polygonatum, 18g of salvia miltiorrhiza, 27g of hawthorn, 18g of spiny jujube seed, 36g of chrysanthemum and 18g of lycium bark;

[0042] The preparation method is as follows:

[0043] (1) Add 5 times the amount of aqueous solution containing 0.02% tartaric acid to white salvia miltiorrhiza, hawthorn and spiny jujube seeds, heat and reflux for extraction once, the extraction time is 2 hours, and filter to obtain the extract and the residue 1;

[0044] (2) Mix wolfberry, astragalus, polygonatum, chrysanthemum and radix rehmanniae, add 5 times the amount of 70% ethanol, heat and reflux to extract for 1 hour, and filter to obtain the alcohol extract and residue 2.

[0045] (3) Mix the residue 1, residue 2, processed Polygonum multiflorum, Epimedium, Ligustrum lucidum, Chinese Angelica sinensis, and Cuscuta australis, add 5 times the amount of water, and then add 1% of the water mass of complex enzyme (the complex enzyme is a mixture of aminopeptidase, cellulase, and β-glycosidase in a ratio of 1:0.04:0.1), perform enzymolysis at 45°C and pH 6 for 1 hour, boil at 100°C for 3 minutes to inactivate the enzyme, and filter to obtain an enzymolysis solution;

[0046] (4) The extract, alcohol extract and enzymatic hydrolyzate are mixed, reduced pressure is applied at 60°C, and vacuum dried to obtain the product.

[0047] Comparative Example 1

[0048] The difference between this comparative example and Example 1 is that the solvent is different. The raw materials are: 18g of wolfberry, 18g of processed polygonum multiflorum, 18g of epimedium, 18g of glossy privet fruit, 24g of angelica, 36g of dodder seed, 27g of astragalus, 36g of processed polygonatum, 18g of salvia miltiorrhiza, 27g of hawthorn, 18g of spiny jujube seed, 36g of chrysanthemum and 18g of lycium bark;

[0049] The preparation method is as follows:

[0050] (1) Add 5 times the amount of aqueous solution containing 0.02% citric acid to Salvia miltiorrhiza, Crataegus pinnatifida and Ziziphus jujuba seeds, heat and reflux to extract twice, each extraction time is 0.5 h, and filter to obtain the extract and the residue 1;

[0051] (2) Mix wolfberry, astragalus, polygonatum, chrysanthemum and radix rehmanniae, add 5 times the amount of 30% ethanol, heat and reflux to extract for 1 hour, and filter to obtain the alcohol extract and residue 2.

[0052] (3) Mix the residue 1, residue 2, processed Polygonum multiflorum, Epimedium, Ligustrum lucidum, Chinese Angelica sinensis, and Cuscuta australis, add 5 times the amount of water, and then add 1% of the mass of water of a complex enzyme (a mixture of aminopeptidase, cellulase, and β-glycosidase in a mass ratio of 1:0.03:0.1), perform enzymolysis at 35°C and pH 6 for 1 hour, boil at 100°C for 3 minutes to inactivate the enzyme, and filter to obtain an enzymolysis solution;

[0053] (4) The extract, alcohol extract and enzymatic hydrolyzate are mixed, reduced pressure is applied at 60°C, and vacuum dried to obtain the product.

[0054] Comparative Example 2

[0055] The difference between this comparative example and Example 1 is that the enzymes are different.

[0056] The raw materials are: wolfberry 18g, processed Polygonum multiflorum 18g, epimedium 18g, Ligustrum lucidum 18g, angelica 24g, Cuscuta 36g, Astragalus 27g, processed Polygonatum 36g, Salvia miltiorrhiza 18g, Hawthorn 27g, Ziziphus jujuba seed 18g, Chrysanthemum 36g and Lycium bark 18g;

[0057] The preparation method is as follows:

[0058] (1) Add 5 times the amount of aqueous solution containing 0.02% tartaric acid to white salvia miltiorrhiza, hawthorn and spiny jujube seeds, heat and reflux to extract twice, each extraction time is 0.5 h, and filter to obtain the extract and the residue 1;

[0059] (2) Mix wolfberry, astragalus, polygonatum, chrysanthemum and radix rehmanniae, add 5 times the amount of 75% ethanol, heat and reflux to extract for 1 hour, and filter to obtain the alcohol extract and residue 2.

[0060] (3) Mix the residue 1, residue 2, processed Polygonum multiflorum, Epimedium, Ligustrum lucidum, Chinese Angelica sinensis, and Cuscuta australis, add 5 times the amount of water, and then add 1% of the mass of water of a composite enzyme (a mixture of pectinase, cellulase, and β-glycosidase in a mass ratio of 1:0.03:0.1), perform enzymolysis at 35°C and pH 6 for 1 hour, boil at 100°C for 3 minutes to inactivate the enzyme, and filter to obtain an enzymolysis solution;

[0061] (4) The extract, alcohol extract and enzymatic hydrolyzate are mixed, reduced pressure is applied at 60°C, and vacuum dried to obtain the product.

[0062] Comparative Example 3

[0063] The difference between this comparative example and Example 1 is that the enzymes are different.

[0064] The raw materials are: wolfberry 18g, processed Polygonum multiflorum 18g, epimedium 18g, Ligustrum lucidum 18g, angelica 24g, Cuscuta 36g, Astragalus 27g, processed Polygonatum 36g, Salvia miltiorrhiza 18g, Hawthorn 27g, Ziziphus jujuba seed 18g, Chrysanthemum 36g and Lycium bark 18g;

[0065] The preparation method is as follows:

[0066] (1) Add 5 times the amount of an aqueous solution containing 0.02% tartaric acid to Salvia miltiorrhiza, Crataegus pinnatifida and Ziziphus jujuba seeds, heat and reflux to extract twice, each extraction time is 0.5 h, filter, and combine the filtrate to obtain an extract and a residue 1;

[0067] (2) Mix wolfberry, astragalus, polygonatum, chrysanthemum and radix rehmanniae, add 5 times the amount of 75% ethanol, heat and reflux to extract for 1 hour, and filter to obtain the alcohol extract and residue 2.

[0068] (3) Mix the residue 1, the residue 2, processed Polygonum multiflorum, Epimedium, Ligustrum lucidum, Chinese Angelica sinensis, and Cuscuta australis, add 5 times the amount of water, and then add 1% of the mass of water of a composite enzyme (a mixture of bromelain, cellulase, and amylase in a mass ratio of 1:0.03:0.1), perform enzymolysis at 35°C and pH 6 for 1 hour, boil at 100°C for 3 minutes to inactivate the enzyme, and filter to obtain an enzymolysis solution;

[0069] (4) The extract, alcohol extract and enzymatic hydrolyzate are mixed, reduced pressure is applied at 60°C, and vacuum dried to obtain the product.

[0070] Experiment 1: Experiment on the efficacy of the composition of the present invention in preventing and treating atherosclerosis

[0071] Experimental animals: 72 SPF SD rats, weighing 220-240g, male. Rats were allowed free access to food and water. The experiment was conducted after one week of adaptive feeding.

[0072] High-fat feed: Add 15% animal oil, 18% sucrose and 3% egg yolk by weight to the basic feed.

[0073] Establishment of animal model of atherosclerosis: 8 rats were randomly selected as the normal group, and the rest were used as the experimental group for modeling. Except for the rats in the normal group who were fed with ordinary granular feed, the rats in other groups were fed with high-fat feed. The rats were free to eat and drink water for 4 weeks. After fasting for 12 hours overnight, the normal group was intraperitoneally injected with the same dose of normal saline. Except for the normal group, the rest of the rats were intraperitoneally injected with 1% STZ (streptozotocin) solution at 45 mg / kg body weight and continued to be fed with high-fat feed for modeling. The experiment lasted for 12 weeks. When HE staining of the model rats showed the formation of atherosclerosis, the modeling was successful.

[0074] Grouping and administration: The model rats were randomly divided into 8 groups: model group, positive group, Example 1, 2, 3 groups, and Comparative Example 1, 2, 3 groups, with 8 rats in each group.

[0075] On the morning of the next day after successful modeling, oral administration began, once a day, and the positive group was given atorvastatin calcium suspension 2 mg / kg;

[0076] The groups of Examples 1-3 and Comparative Examples 1-3 were given the Chinese medicine compositions prepared by the corresponding groups, and the Chinese medicine compositions were dissolved and dispersed in warm water, and the dosage was 3 g of crude drug / kg;

[0077] The normal group was given the same dose of normal saline;

[0078] The rats were given the drug by oral gavage continuously for 12 weeks. The rats were fasted but not watered for 12 hours and then sacrificed. The rats were anesthetized by intraperitoneal injection of 3% sodium pentobarbital at 2 mL / kg. Blood was collected from the femoral artery, serum was separated, and biochemical indicators were measured by ELISA to evaluate the levels of total cholesterol, triglycerides, low-density lipoprotein, and high-density lipoprotein.

[0079] The aorta was dissected, and a portion of the aortic tissue was cut and placed in a cell cryopreservation tube. The relative expression levels of MMP-9 mRNA and PPAR-γ mRNA in the aorta were detected by fluorescent real-time quantitative PCR.

[0080] The results are shown in Tables 1-3.

[0081]

[0082] Table 2

[0083]

[0084] Note: Compared with the normal group, * P<0.01; compared with the model group, # P<0.05, ## P<0.01; compared with the Example 1 group, △ P<0.05.

[0085]

[0086] Experiment 2 Summary of clinical cases treated with the composition of the present invention

[0087] 2.1 Materials and Methods

[0088] General data were collected from inpatients and outpatients of the Department of Traditional Chinese Medicine of the First Affiliated Hospital of Fujian Medical University. The inclusion criteria were as follows:

[0089] 1) Ultrasonic diagnosis of carotid intima-media thickness (IMT)>1.0mm and presence of plaques.

[0090] 2) Able to take medication for 12 weeks and meet the conditions for clinical follow-up.

[0091] 3) Age: 43-75 years old.

[0092] 4) The clinical manifestations vary depending on the organs involved: coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia and gout caused by atherosclerosis.

[0093] The criteria for exclusion of cases were as follows:

[0094] 1) Carotid artery ultrasound shows severe intraluminal plaques leading to blood flow obstruction;

[0095] 2) Carotid IMT <I.Omm 3 , patients with acute myocardial infarction, heart failure, and acute cerebrovascular disease.

[0096] A total of 60 patients who met the above conditions were enrolled and randomly divided into a treatment group and a positive control group according to the random number table method. There was no significant difference in general data such as age, disease course, and condition between the two groups of patients (P>0.05), and they were comparable.

[0097] The experimental group included 30 cases, including 15 males and 15 females, aged 45-78 years old, including 9 cases of coronary heart disease, 15 cases of hypertension, 10 cases of hyperlipidemia, 9 cases of hyperglycemia, and 12 cases of hyperuricemia.

[0098] There were 30 cases in the positive control group, including 12 males and 18 females, aged 45-75 years old, including 10 patients with coronary heart disease, 12 patients with hypertension, 8 patients with hyperlipidemia, 11 patients with hyperglycemia, and 9 patients with hyperuricemia.

[0099] Treatment method: The treatment group was given the Chinese medicine composition prepared in Example 1, 2 g once, once in the morning and once in the evening; the positive control group was given atorvastatin calcium (2 tablets each time, 10 mg each), and the two groups of patients were treated continuously for 12 weeks. High-resolution ultrasound was used to non-invasively detect the structure of the carotid artery wall, the morphology of plaques and hemodynamics in patients with carotid atherosclerosis. A biochemical analyzer was used to detect total cholesterol (Tc), triglycerides (Tg), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), high-sensitivity C-reactive protein (hs-CRP) and fibrinogen (Fib) and related analysis was performed.

[0100] Efficacy evaluation criteria:

[0101] Markedly effective: The corresponding clinical symptoms are significantly alleviated, complications are significantly improved, and blood pressure, blood lipids, blood sugar, and uric acid drop to near normal levels;

[0102] Effective: The corresponding clinical symptoms are alleviated, complications are slightly improved, and blood pressure, blood lipids, blood sugar and uric acid levels drop by less than 20%;

[0103] Ineffective: There is little improvement in clinical symptoms and signs.

[0104] The results are shown in Table 4:

[0105] Table 4

[0106]

[0107] Conclusion: The Chinese medicine composition prepared in Example 1 of the present invention has multiple components synergistically acting on multiple targets, and has obvious advantages in improving the treatment of coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis, while the positive control group only has significant effects on coronary heart disease and hyperlipidemia.

[0108] The above-mentioned embodiments only express several implementation methods of the present invention, and the description thereof is relatively specific and detailed, but it cannot be understood as limiting the scope of the patent of the present invention. It should be pointed out that, for ordinary technicians in this field, several variations and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. Therefore, the protection scope of the patent of the present invention shall be subject to the attached claims.

Claims

1. A Chinese medicine composition for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis, characterized in that: The raw materials of the composition are as follows: 18 parts of wolfberry, 18 parts of processed Polygonum multiflorum, 18 parts of epimedium, 18 parts of Ligustrum lucidum, 24 parts of angelica, 36 parts of Cuscuta australis, 27 parts of Astragalus, 36 parts of Polygonatum, 18 parts of Salvia miltiorrhiza, 27 parts of Crataegus, 18 parts of Ziziphus jujuba seeds, 36 parts of chrysanthemum and 18 parts of Lycium bark by weight; the preparation method of the composition comprises the following steps: (1) extracting salvia miltiorrhiza, hawthorn and spiny jujube seeds with a solvent, and filtering to obtain an extract and a medicinal residue 1; (2) extracting wolfberry, astragalus, polygonatum, chrysanthemum and lycium bark with alcohol to obtain an alcohol extract and a medicinal residue 2; (3) Mixing the residue 1, the residue 2, processed Polygonum multiflorum, Epimedium, Ligustrum lucidum, Chinese Angelica sinensis, and Cuscuta australis, and performing enzymolysis to obtain an enzymolysis solution; (4) Mix the extract, alcohol extract and enzymatic hydrolysate and dry them; The solvent in step (1) is an aqueous solution containing 0.01-0.02% tartaric acid; The enzyme used in the enzymatic hydrolysis in step (2) is a mixture of aminopeptidase, cellulase and β-glycosidase.

2. The Chinese medicine composition according to claim 1, characterized in that: The extraction times in step (1) are 1-3 times, the time of each extraction is 0.5-2h, and the extraction is heating reflux extraction.

3. The Chinese medicine composition according to claim 1, characterized in that In step (1), the salvia miltiorrhiza is salvia miltiorrhiza.

4. The Chinese medicine composition according to claim 1, characterized in that: The alcohol extraction in step (2) is performed using 70-75% ethanol, and the extraction is performed by heating reflux extraction.

5. The Chinese medicine composition according to claim 1, characterized in that: The mass ratio of the aminopeptidase, the cellulase and the beta-glycosidase is 1:0.02-0.05:0.1-0.

2.

6. The Chinese medicine composition according to claim 1, characterized in that: The temperature of the enzymolysis is 30-45° C., the time of the enzymolysis is 1-2 hours, and the pH of the enzymolysis is 6-7.

7. A pharmaceutical preparation, characterized in that The invention comprises the Chinese medicine composition according to any one of claims 1 to 6 and pharmaceutically acceptable excipients.

8. Use of the Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a medicament for preventing and treating coronary heart disease, hypertension, hyperlipidemia, hyperglycemia or hyperuricemia gout caused by arteriosclerosis.